Sabrina Ronen, professor in the Department of Radiology Biomedical Imaging at UCSF, is focused on developing new, non-invasive imaging biomarker indicators that characterize tumors. Ronen and her team are developing bio-markers that enable them to confirm delivery of a drug to the tumor. Once the oncologist has this information s/he can determine how to treat the patient in a much more precise and personalized way, targeting the treatment to the individual tumor. In this manner, the Ronen lab addresses breast cancer, prostate cancer and the higher-grade aggressive glioblastoma brain tumors as well as lower-grade, somewhat less aggressive brain tumors. They are pushing the envelope to work toward improving patient outcomes. There is a persistent challenge of resources and funding for students and postdocs, as well as equipment in the lab. The team focuses on the science and on delivering the very best possible imaging to the patient in-trial and in-clinic. The translation of research to the clinic provides us the ultimate achievement of our goals. Profile: Sabrina M. Ronen, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Ronen completed her BS in Chemistry and Biochemistry at the Hebrew University in Jerusalem, Israel, received her MS in Chemistry from San Jose State University, and obtained her PhD in Chemical Physics from The Weizmann Institute of Science in Rehovot, Israel. She then trained as a postdoctoral fellow at the Institut Curie in Paris, France, and started her academic career at the Institute of Cancer Research in London, England. Dr. Ronen’s Laboratory focuses on developing and mechanistically validating robust non-invasive translatable magnetic resonance (MR)–based biomarkers that can be used to monitor oncogenic transformation and response to therapy. Dr. Ronen has ongoing research projects on monitoring PI3K signaling, detecting the mutational status of isocitrate dehydrogenase, probing the metabolism of brain tumors, and determining the metabolomic profile of pancreatic cancer. Expertise: Magnetic resonance spectroscopy (MRS), spectroscopic imaging (MRSI), imaging (MRI), metabolism, cancer, bioengineering Specialty: Preclinical cancer models Professional Interests: Magnetic resonance, spectroscopy, imaging, cancer, metabolism, cell signaling, biomarkers Education and Training: • Bachelor of Science: Hebrew University, Jerusalem, Israel - Cum Laude, Chemistry and Biochemistry • Masters of Science: San Jose State University, San Jose - Chemistry • Doctor of Philosophy: Weizmann Institute of Science, Rehovot, Israel - Chemical Physics • Postdoctoral Fellowship: Institut Curie, Paris, France - Imaging • Postdoctoral Fellowship: Harefield Hospital, London, England - Imaging
Views: 365 UCSF Imaging
What do you rely on when you form an opinion? Do you think about your past experiences or do you research your questions in search of fact? Through tales of her own scientific research, Dr. Kelly O'Connell discusses how the Scientific Method can be used to form opinions from assessing models of heart disease to baking cookies. During her time at St. Lawrence University, Dr. Kelly O’Connell played NCAA volleyball, studied abroad in France, and regularly participated in scientific research. After graduating with a Bachelor’s degree in biochemistry in 2008, she moved to Boulder, CO and worked for ThermoFisher Scientific before entering graduate school at the University of Maryland School of Medicine in Baltimore, MD. Her graduate research explored how changes in mitochondrial function affect the progression of heart failure. After receiving her Ph.D., she accepted a post-doctoral fellowship position at Brown University to study the molecular mechanisms of cardiac dysfunction in pulmonary hypertension. Kelly now works as an Applications Scientist for FUJIFILM VisualSonics, where she focuses on high frequency ultrasound and photoacoustic imaging. Outside of the lab, Kelly and her husband live in the Boston area where they enjoy the cultural activities in the city and hiking in the mountains of New Hampshire. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx
Views: 444 TEDx Talks
Dr. Taylor Schoberle began her training in the biological sciences at Southwestern University, where she earned a B.A. in Biology with a minor in French. She moved on to MD Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences in Houston to earn an M.A. in Molecular Biology and Genes and Development, followed by a Ph.D. in Biomedical Sciences. Although her graduate research focused on toxin production in Aspergillus fumigatus, a filamentous fungus, she has successfully carried her lab techniques and knowledge into her current post doctoral position as a NY-CAPS scholar in Dr. James Bliska’s lab at Stony Brook University. Dr. Schoberle’s current research focuses on the Type III Secretion system in Yersinia pestis, the etiological agent of the Plague. Y. pestis, as well as numerous other gram negative bacteria, utilize a Type III Secretion system to combat immune cells when invading a host. Upon induction, assembly of this Type III Secretion system commences to form a hollow needle-like complex of proteins. This needle complex is responsible for injecting effector proteins (Yops) into host cells. Once inside host cells, these Yops interfere with multiple cell functions to deter an immune response against invading bacteria.
Views: 113 CIE Stony Brook
In his first town hall meeting, NCI Director, Dr. Norman Sharpless, highlights a few broad areas where he believes NCI has a role to play in advancing progress against cancer. https://www.cancer.gov/about-nci/leadership/director/presentations
Views: 705 National Cancer Institute
When will we decide to conquer chronic disease? The moment we realize the future’s not only in our genes but also in our hands with the choices we make regarding food and nutrition. We now know how we grow before we are born, matters. A woman who is pregnant with a daughter is nourishing the egg that may someday become her grandchild. We must remove the vulnerability for developing chronic disease before it starts. Through the right choices in Family, School, Workplace & Policy - we can position humanity towards a sustainable, more livable answer. Dr. Kent L. Thornburg received his PhD in Developmental Physiology and studied Cardiovascular Physiology as a National Institutes of Health (NIH) Postdoctoral Fellow at Oregon Health & Science University (OHSU). He participates in co-funded projects with scientists in England, New Zealand, France, Finland and Australia. He serves regularly on advisory panels at the NIH, the American Heart Association and the Children’s Heart Foundation and recently served as Co-Chair of the task force to determine the 10-year vision of the developmental origins of health and disease for the National Institute of Child Health and Human Development. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 86789 TEDx Talks
Take a closer look at Squale Watches 50 ATM diver's watch. This 500 metre rated watch, also known as the 1521, is fast becoming a modern classic from a watch manufacturer with a truly fascinating history. Available from Page and Cooper: http://www.pageandcooper.com/?t=social
Views: 28151 Page and Cooper
For his PhD Sam Merlin studied a gene that helps guide nerve connections in the developing brain. Just finishing up his PhD work he is about to leave Sydney for a postdoctoral research position studying the mechanisms of visual perception, at University of Utah, Salt Lake City. Interview and video made by Neuroscience students Jean Sandig and Jean Kate Speakman.
Views: 1017 LRDHAVEMERCY
Michael Ursell, PhD, University of California Santa Cruz, talks about his research and experience as a Postdoctoral Fellow (2013-14) at the Bill and Carol Fox Center for Humanistic Inquiry. The Bill and Carol Fox Center for Humanistic Inquiry stands for the central role of the humanities in the life of Emory University and beyond. The Center promotes individual research, while also increasing the impact of the humanities across the University and, ultimately, the world. http://chi.emory.edu
Views: 370 Emory University
Dr. Christina Sanchez, a molecular biologist at Compultense University in Madrid, Spain explains how THC kills cancer cells. Cristina Sánchez (Madrid, Spain, 1971) graduated in Biology at Madrid Complutense University in 1994. Once graduated, she joined Dr. Manuel Guzmán's laboratory, where she studied the effect of cannabinoids on lipid and carbohydrate intermediate metabolism first and on cancer cell proliferation later. She obtained her PhD with Honors in Biochemistry and Molecular Biology at Complutense University in 2000. During her postdoc at Dr. Piomelli's laboratory (University of California Irvine, 2000-2003) she studied the involvement of another group of bioactive lipids (lysophosphatidic acid and related compounds) on pain initiation. In 2004, Cristina returned to Spain and she started coordinating a new line of research within Dr. Guzmán's laboratory. The goal of her research is to understand and exploit cannabinoids as potential antitumoral agents in breast cancer. More recently, she has also focused her attention on new cannabinoid receptors and their possible involvement in cannabinoid antitumoral action in breast cancer and other type of tumors.
Views: 183116 Lincoln Horsley
- No matter who you are as a job candidate, there will be pros and cons. As a PhD, an employer may wonder if you have certain transferable skills or if you understand industry. One thing is certain: if you are the top candidate for the job, you will be hired. - Don’t let your degree or an intimidating job description be an excuse for not applying. If they ask for 2-5 years of industry experience, apply. If they ask for a Master’s degree and you have a PhD, apply. - Often hiring managers will adapt the role to the candidate. If you are a PhD and are applying for a job that requires a Master’s degree, the hiring manager will change the position to a more senior level or suggest that you apply for a more senior role in the company. If you prove your value, they will find a way to hire you. For more job search tips including a full review of the top 40 Online Networking Scripts For PhDs, get this FREE ebook: https://cheekyscientist.com/40-networking-scripts/
Views: 252 Cheeky Scientist
https://www.labtv.com/Home/Profile?researcherId=2245 Meet Ziwei Li, a post-doc in the Amander Clark Lab at UCLA. Ziwei’s research involves studying regenerative properties of stem cells with the goal of using stem cells to treat infertility. To learn more about Ziwei, visit https://www.labtv.com/Home/Profile?researcherId=2245.
Views: 12911 LabTV
Vice-President of Business Development at IRICoR (Université de Montréal), Steven Klein, and Director of Government Relations & Public Affairs at Bristol-Myers Squibb Canada, Donald Allard, discuss th
An enlightening and provocative presentation is given by Valter Longo updating audience on the benefits of fasting for life-extension. Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences, and Director of the Longevity Institute at the University of Southern California – Davis School of Gerontology, Los Angeles. Dr. Longo’s studies focus on the fundamental mechanisms of aging in simple organisms, mice and humans. The Longo laboratory has identified several genetic pathways that regulate aging in simple organisms and reduce the incidence of multiple diseases in mice and humans. His laboratory also described both dietary and genetic interventions that protect cells and improve the treatment and prevention of cancer and other diseases in mammals. He received his Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA) in 1997 and his postdoctoral training in the Neurobiology of Aging and Alzheimer’s Diseases at USC. He started his independent career in 2000 at the University of Southern California, School of Gerontology. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 383671 TEDx Talks
Full title: Analysis of peripheral T-cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens Mastering Immunity Europe 2017 Centre de Recherche des Cordeliers, UPMC, France It is now well established that many tumors are under the surveillance of the host immune system and that anti-tumor adaptive responses are critical for the clinical outcome of patients. One consequence of this paradigm is that monoclonal antibody (mAb) therapy that had been viewed for a long time only as acting through the involvement of innate immunity is now thought to be efficient due to its ability to trigger or reinforce adaptive anti-tumor responses. Notably, reports based on in vivo preclinical models using CD20+ or HER2/neu+ tumor-bearing mice have suggested that anti-CD20 or anti-HER2/neu mAb treatments lead to long-term survival through the induction of adaptive T-cell anti-tumor responses, considered as a “vaccine effect”. 1,2,3,4 Thus, the aim of the present study was to monitor changes in adaptive immune T-cell compartments in peripheral blood from Follicular Lymphoma (FL) patients during anti-CD20 (rituximab, RTX) treatment using multi-parametric phenotyping, transcriptomic and functional analyses. High-grade FL patients (n=30) were enrolled in the study. Blood samples were obtained before treatment (T0), during RTX infusion combined to CHOP chemotherapy regimen (T-R-CHOP), and during RTX maintenance therapy (T-Rm). Multi-parametric flow cytometry analysis underlined profound differences in naive, regulatory and memory T-cell compartments between patients at diagnosis (before therapy) and healthy donors. Furthermore, inhibitory immune checkpoints expressing-T cells were much more frequent in the blood of patients compared to healthy donors. Hierarchical clustering of patients based on the integrative analysis of flow cytometry data showed differential activation status of peripheral T cells among individuals prior to any treatment. Follow-up of blood T-cell compartments by flow cytometry during treatment showed an overall decrease in the percentage of regulatory T cells and T cells expressing inhibitory checkpoints. Several clusters of patients could be defined, according to different parameters analyzed throughout the treatment. Transcriptomic analysis of immune-related genes in 16 patients revealed that 174 genes were significantly differentially expressed between T0 and T-RCHOP, 68 between T-R-CHOP and T-Rm, and 61 between T-Rm and T0, indicating that the major changes occurred during initiation treatment. The frequencies of individuals exhibiting T-cell responses against CMV/Flu/EBV peptides or immunogenic CD20 peptides (defined by in silico, in vitro and in vivo approaches) were similar between patients and healthy donors. However, the intensity of specific T-cell responses was lower in all the patients tested, although these responses appear to be heterogeneous. Overall, T-cell compartments are profoundly affected in patients with high-grade FL prior any treatment. Our data indicate that R-CHOP followed by RTXm modulates T-cell activation status and function in a heterogeneous way among FL patients. The hierarchical clustering of patients based on the phenotypic and functional analysis of T-cell compartments pave the way for the definition of new immune biomarkers correlating with the clinical outcome of patients. Sophie Sibéril is currently Assistant Professor of Immunology at Pierre et Marie Curie University and has worked since 2012 on mechanisms of action of anti-tumor monoclonal antibodies in “Immune Control and Escape" Laboratory (Cordeliers Research Center, Paris, France). She received her Ph.D. in Immunology from the Pierre et Marie Curie University in 2005, working with Dr. Jean-Luc Teillaud on the impact of IgG N-glycosylation on the effector functions of monoclonal antibodies. She had a post-doctoral position in the team of Dr. Sylvain Latour (Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, Necker Hospital, Paris, France) where she focused on the homeostasis of invariant natural killer T cells (iNKT) lymphocytes and on their susceptibility to apoptosis in X-linked lymphoproliferative syndrome. From 2009 to 2012 she joined the team of Dr. Behazine Combadière (Pitié-Salpêtrière Hospital, Paris, France) whose research activity focuses on the analysis of intensity, quality and maintenance of adaptive immune responses after vaccination and the development of new vaccine strategies against infectious pathogens. Sophie Sibéril currently develops a research project in the team of Dr. Jean-Luc Teillaud concerning the impact of anti-CD20 mAb-based treatment on adaptive immunity of patients with lymphoma.
Views: 129 ProImmune thinkpeptides
Dr Bahija Jallal, Executive Vice President of AstraZeneca & Head of MedImmune speaking about why she helped bring GapSummit to USA, innovation and the field of biologics, at GapSummit 2017, world's premier inter-generational leadership summit in biotechnology at Georgetown University, Washington DC, USA. Interviewer: Dr. Marina Carla Cabrera (President, GapSummit 2017). Dr. Bahija Jallal is Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She has guided the MedImmune R&D organization through unprecedented expansion of its biologics pipeline from 40 drugs to more than 120 today. She inspires creativity, out-of-the-box thinking and a dedication to scientific excellence to the more than 2,500 employees at MedImmune. She received a master’s degree in biology from the University of Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, and the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory member of the Healthcare Business Women’s Association. She is one of FierceBiotech’s 2011 Women in Biotech. She has received Washington Business Journal’s Women Who Mean Business Award, the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research, and the Maryland International Business Leadership Awards.
Views: 175 GlobalBiotechRevolution
Media personality and patient advocate Valerie Smaldone and Dr. Francis Arena, co-Founder of the SASS Foundation, ring The Closing Bell® to highlight Ovarian Cancer Awareness month. A five-time Billboard Magazine Award winner, Valerie is perhaps best known for her years of success holding the #1 position in the New York radio market as the midday host of New Yorks Lite FM, 106.7. In addition, she was a creator and host of 'Spotlight On,' a nationally syndicated radio program that featured in-depth interviews with top recording artists such as Paul McCartney, Elton John, Sting and Celine Dion. Valerie also conceived, produced and hosted a talk/music program geared toward women for Clear Channel online. As a patient advocate, Valerie has spoken on behalf of ovarian cancer patients regarding the psychological effects of the disease. She was a recent guest speaker at a medical conference at the Oncology Society of Bari, Italy, has received numerous awards for her humanitarian work including the World Foundation for Medical Studies in Female Health, and The Sass Foundation, and has been a spokesperson and fundraiser for The Ovarian Cancer Research Fund, the Ovarian Cancer National Alliance and the National Ovarian Cancer Coalition. About Francis P. Arena, M.D., F.A.C.P., Board Certified Internal Medicine and Oncology Francis P. Arena, MD, FACP is a product of one of the most renowned cancer centers in the world, Memorial Sloan-Kettering Cancer Center. Because of his keen interest in cancer research, Dr. Arena helped establish the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9," the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies. About the SASS Foundation The SASS Foundation for Medical Research, a 501(c) (3)non-profit organization, is committed to education, research, and education in various hematological and malignant diseases. As a part of research commitment, the SASS Foundation offers four research grants annually to bright young post-doctoral fellows to pursue innovative ideas that have the potential to develop into independent investigators with sustained extramural NIH type funding. The amount of funding is $40,000 for one year, which can be competitively renewed for a second year. Link to related URL : http://sassfoundation.org/
Views: 259 NYSE
Title: Plasma metabolomic signature of novel signal transduction inhibitors: From preclinical identification to clinical validation. 3rd International Conference and Exhibition on Metabolomics & Systems Biology March 24-26, 2014, San Antonio, USA OMICS International: http://omicsonline.org Vaccine Conferences: http://conferenceseries.com/immunology-conferences.php Global Medical Conferences: http://conferenceseries.com Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com Global Cancer Conferences: http://cancersummit.org Global Diabetes Conferences: http://diabetesexpo.com Global Dental Conferences: http://dentalcongress.com Global Nursing Conferences: http://nursingconference.com Abstract Early clinical studies of novel agents evaluate both pharmacokinetic and pharmacodynamic profiles. In preclinical oncology studies, the biomarker of interest can be measured in tumor material but in clinical development, not all tumors are accessible and patients cannot be regularly biopsied. Therefore, identification of circulating biomarkers is extremely useful in assisting clinical development of novel oncology products. We have been using non-targeted followed by targeted LCMS to evaluate if plasma metabolomics can be used to monitor the effect of novel signal transduction inhibitors. We show that significant differences in the plasma metabolome of genetically engineered PTEN+/- mice when comparing with littermate controls and in mice bearing PTEN-/- human tumor xenografts compared with non-tumor bearing animals. This signature can be reversed by a PI3K inhibitor. The plasma metabolomic signature of nude mice bearing a B-RAF of K-RAS mutant tumor xenograft is different to that observed in PTEN-/- animals and can be reversed using a MEK inhibitor in mice bearing human tumour xenograft. The metabolic signatures include amino acids, carnitine derivatives and lipids some of which are affected by time of day and food intake. Therefore, the effect of food and sampling time need to be incorporated in the analysis. Despite these variations, the preclinical signatures identified following a PI3K or MEK inhibitor can be observed in patients following treatment with a pan class I PI3K inhibitor and a MEK inhibitor. These data suggest that plasma metabolomic is a valid strategy to monitor the pharmacodynamic development of novel anticancer agents. Biography Florence I. Raynaud completed her Ph.D. at the University of Strasbourg, France where she carried out her first post-doctoral position. She is currently leader of the drug metabolism and pharmacokinetics team at the Institute of Cancer Research where she is involved in the preclinical and clinical development of novel anticancer agents. She has been involved in the preclinical development of 20 novel agents that have reached clinical trials. These include abiraterone which has been registered for advanced prostate cancer. She is the author of over 100 publications and is on the editorial board of Clinical Cancer Pharmacology.
Views: 131 Dental and Oral Health 2014
http://www.fulbright.be - Koen Putman, received a grant from the Fulbright Commission and the Belgian-American Educational Foundation in Belgium in order to do postdoctoral research in the United States. Mr. Putman chose to do research on rehabilitation sciences at Georgetown University and the National Rehabilitation Hospital in Washington, DC.
Views: 2408 Fulbright Belgium, Luxembourg and EU
(Visit: http://www.uctv.tv/) 1:46 - How We Determine What Food Fueled Human Evolution - Margaret Schoeninger 20:49 - Nutritional Significance of Meat - Alyssa Crittenden 36:26 - How Control of Fire Changed Hunting - Richard Wrangham Hunting is considered a key human adaptation and is thought to have influenced our anatomy, physiology and behavior over time. This symposium explores the evidence pertaining to the origins of hominin hunting. Series: "CARTA - Center for Academic Research and Training in Anthropogeny" [5/2018] [Show ID: 33566]
Views: 7784 University of California Television (UCTV)
Presented by: Larry Smith, PhD - Manager, Medical and Scientific Affairs, Hematology, Abbott Diagnostics Speaker Biography: Dr. Larry Smith received his doctorate in biological sciences from Fordham University, Bronx, New York, and completed his certificate in molecular laboratory diagnostics at Michigan State University, East Lansing, Michigan. He completed his postdoctoral studies in gene therapy and experimental hematopoiesis at Columbia University College of Physicians and Surgeons, New York, New York, and was a research fellow in immunology at Fordham University and at the Laboratory of Lymphokine Biology at the New York Blood Center's Lindsley F. Kimball Research Institute, New York, New York. In addition, Dr. Smith has a Master of Science in medical biology and a Bachelor of Science in French and biology. His former positions include Research Associate and Director of the Stem Cell Research Laboratory, Division of Hematology-Oncology, at Long Island College Hospital, Brooklyn, New York; Adjunct Associate Professor at Rutgers School of Health Related Professions, Newark, New Jersey; Adjunct Professor at the School of Health Sciences and Professional Programs, York College, City University of New York, Jamaica, New York; and Director of the Coagulation and Hemostasis Laboratories, Assistant Attending Laboratory Scientist for the Department of Clinical Laboratories, and Associate Director of Clinical Hematology Laboratories at Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Smith is a member of the American Association for Clinical Chemistry, the Academy of Clinical Laboratory Physicians and Scientists, the American Society for Clinical Pathology, the American Society of Clinical Laboratory Science, the American Society of Hematology, the International Academy of Clinical and Applied Thrombosis/Hemostasis, the International Society for Laboratory Hematology, and the International Society on Thrombosis and Hemostasis. Dr. Smith holds multiple board certificates and has published numerous peer-reviewed articles, abstracts, reviews and monographs. He is the co-author of several textbooks on hematology and coagulation and has been an invited presenter at both national and international conferences. His research interests include laboratory test development for hemostasis and coagulation, HPC therapeutic applications, and flow cytometry. Webinar: Laboratory Diagnosis of von Willebrand Disease (VWD) Abstract: von Willebrand Disease (vWD) is one of the most common congenital bleeding disorders, affecting ~1%* of the world’s population. An accurate diagnosis can be very challenging due to the heterogeneity of the disorder and preanalytical variables that may affect the assays used in the diagnosis. Clinical laboratories may perform both screening and complex assays to measure different properties and activities of von Willebrand factor (vWF) to aid clinicians with diagnosis. However, these assays may be adversely affected by preanalytical variables and often have altered performance characteristics that may contribute to inadequate interpretation. In this webinar, Dr. Larry Smith, Abbott’s coagulation expert with over 30 years of clinical laboratory experience, will: -Define vWD and its history -Go over current classification of vWD and assays utilized -Review structure and function of vWF -Discuss methods/technologies for diagnosing vWD, assay limitations, and preanalytical variables influencing vWD testing and interpretation Sponsored By: Abbott Diagnostics Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/laboratory-diagnosis-von-willebrand-disease-vwd) 2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/laboratory-diagnosis-von-willebrand-disease-vwd) 3. Click Here to get your PACE credits (Expiration date – December 14, 2019 06:00 AM) - http://www.labroots.com/credit/pace-credits/2669/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Views: 243 LabRoots
What do the intestines have to do with boosting the immune system? Dr. Constance Finney explains. As a CTN postdoctoral fellow she worked on assessing the pathogenic role of macrophages (white blood cells within tissues) in the gut during HIV infection (host perspective). Her supervisor was Dr. John Gill at the University of Calgary. Her fellowship sponsors were CANFAR and the CTN. She is now assistant professor of immunology at the University of Calgary. http://www.hivnet.ubc.ca
Views: 409 CIHR CTN
AI for Health Needs Causality David Sontag, PhD Hermann L. F. von Helmholtz Career Development Professor of Medical Engineering, Massachusetts Institute of Technology Assistant Professor of Electrical Engineering and Computer Science, Massachusetts Institute of Technology Recent success stories of using machine learning for diagnosing skin cancer, diabetic retinopathy, pneumonia, and breast cancer may give the impression that artificial intelligence (AI) is on the cusp of radically changing all aspects of health care. However, many of the most important problems, such as predicting disease progression, personalizing treatment to the individual, drug discovery, and finding optimal treatment policies, all require a fundamentally different way of thinking. Specifically, these problems require a focus on *causality* rather than simply prediction. Motivated by these challenges, my lab has been developing several new approaches for causal inference from observational data. In this talk, I describe our recent work on the deep Markov model (Krishnan, Shalit, Sontag AAAI’17) and TARNet (Shalit, Johansson, Sontag, ICML ’17).
Views: 56 HarvardDBMI
The YASE meeting (Toulouse 6th July 2018) will be dedicated to African PhD candidates and post docs working in Europe. La conférence YASE (Toulouse, 6 juillet 2018) sera consacrée aux doctorants ou post-doctorants Africains travaillant en Europe. www.yase-conference.eu https://www.facebook.com/yase2018/ https://twitter.com/YASE2018 Video: Anthony Audureau Full text below / Retranscription ci-dessous Yvonne Mburu, docteure en immunologie et fondatrice de medinafrica.com Pourquoi avez-vous quitté l’Afrique pour votre doctorat ? C’est plutôt par chance. J’ai eu la chance d’aller au Canada après mes études au lycée. J’ai eu une bourse partielle pour aller à York University où j’ai étudié la biologie et la chimie. Après j’ai eu une bourse complète pour aller à l'université de Pittsburgh, aux États-Unis. Et là j’ai fait mes études doctorales en immunologie. J’ai étudié le système immunitaire et pourquoi ça ne soigne pas en cas de cancer. Après, j’ai postulé un peu partout dans le monde et j’ai eu l’opportunité d’intégrer une équipe à l’institut Curie qui travaillait encore sur les questions d’immunologie et cancer. Donc pourquoi le système immunitaire n’arrive pas à soigner un cancer comme toute autre maladie. Pourquoi n’avez-vous pas choisi de retourner en Afrique ? J’ai eu justement cette envie de rentrer dans mon pays en 2012. Ma tante est morte d’un cancer et ma famille me demandait à chaque fois : « Tu fais des études de recherches sur le cancer, qu’est-ce que tu peux faire pour ta tante, ton pays et ton continent ? ». Et j’ai eu ce moment qui m’a interpellé. Comment ça se fait que la recherche que je fais n’est pas forcément appliquée aujourd’hui en Afrique. J’ai voulu rentrer mais c’était très difficile de trouver des laboratoires qui faisaient la même recherche que je faisais en France. Et c’est à ce moment-là que j’ai décidé de lancer mon projet qui est une plateforme de la diaspora africaine et des Africains eux-mêmes. L’idée c’est de cartographier, savoir qui est où et qui fait quoi pour que l’on puisse créer des vrais liens entre les gens, des réseaux de connaissances sur le même sujet. Des fois même des sujets transversaux qui touchent une maladie mais traité par différents spécialistes. De savoir aussi comment promouvoir la recherche africaine qui n’est pas valorisée comme il faut et donc avoir cette communauté mondiale et qui travaille ensemble d’une manière organisée. Aujourd’hui il n’existe pas vraiment de système qui nous rassemble comme ça. Avez-vous des projets de retour en Afrique ? Je suis toujours en France, j’ai fait un petit peu de testing des gens pour voir en fait est-ce que c’est possible vraiment. Moi je ne crois pas que la plupart des gens vont rentrer. Je pense qu’à un moment donné, on s’est établi à l’étranger et c’est très difficile de revenir travailler en Afrique surtout dans les sciences et la médecine où il y a quand même un niveau d’infrastructure très élevé pour pouvoir exercer son métier correctement et qui n’est pas forcément partout en Afrique. Que diriez-vous aux jeunes Africains qui font leur doctorat en Europe et veulent retourner en Afrique ? Ce qui est bien avec ma plateforme, c’est qu’on rassemble des gens à la fois en Afrique et à l’étranger. Et donc les gens qui ont envie un jour de travailler en Afrique, de rentrer en Afrique, ou même juste d’avoir des projets avec des sujets qui sont traités ici en Afrique, avec des chercheurs Africains. Ça leur donne cette opportunité de se retrouver, chacun s’inscrit avec ses identifiants. Là on peut par exemple dire je suis immunologue kényane et je cherche d’autres immunologues qui sont peut-être en Zambie, en Afrique du Sud, au Niger etc. Cela permet de savoir ce qui se passe en Afrique pour les gens qui sont à l’étranger, et pour ceux qui sont en Afrique, de savoir où sont tel ou tel personne dans le monde. C’est un lieu qui permet de se retrouver. Yvonne Mburu, PhD in immunology and founder of medinafrica.com ----- Why did you leave Africa for your PhD? It was luck. I had the opportunity to go to Canada after high school. I had a partial scholarship to York University where I studied biology and chemistry. Then, I obtained a scholarship to go to the University of Pittsburgh, in the United States, where I did my PhD in immunology. After that, I applied for post-doctoral positions almost all over the world, and I ended up joining a team at the Curie Institute which worked on immunology and cancer. Precisely, why the immune system does not identify and treat cancer like it does other diseases. ...
Views: 61 Afriscitech.com
TRACO - Ovarian Cancer & TGF-beta Air date: Monday, September 30, 2013, 4:00:00 PM Description: Ovarian Cancer & TGF-beta For more information go to http://ccr.cancer.gov.careers.courses/traco Author: C. Annunziata, S. Jakowlew Runtime: 01:43:30 Permanent link: http://videocast.nih.gov/launch.asp?18121
Views: 630 nihvcast
Surinder Batra, Ph.D., is chair and professor in the Department of Biochemistry and Molecular Biology and the Stokes-Shackelford Distinguished Professor in the College of Medicine at the University of Nebraska Medical Center. He wins the 2016 Outstanding Research and Creative Activity Award from the University of Nebraska system. Together with colleagues at UNMC, Batra has helped make the medical center’s pancreatic cancer research program one of the best of its kind. After completing graduate studies in biochemistry in India and France, Batra completed a fellowship in biochemistry at North Carolina State University. He went on to receive postdoctoral training at Duke University Medical Center. He previously served as senior associate dean of research and development in the College of Medicine and the Helen Freytag Professor of Cancer Biology at UNMC. Batra’s current lab has cloned and patented mucin genes being investigated for the diagnosis and therapy of pancreatic cancer. In a series of papers, his lab has shown the diagnostic potential of the mucin gene MUC4 and implications in the progression and metastasis of pancreatic cancer. His research has been continuously funded by multiple and he has published more than 360 papers in high-impact journals and received several U.S. patents.
Views: 488 University of Nebraska
Andrew and Nicola Forrest announced the first recipients of the prestigious Forrest Research Foundation Scholarships – with the five recipients flying in from around the world to accept their scholarship. Forrest Research Foundation Scholarships are available to international and Australian students who wish to undertake a Doctor of Philosophy (PhD) at one of Western Australia’s five universities. The scholarship recipients are: * Dulce Vargas Landin, from Mexico, who is studying the epigenome in brain function; * Timothy Hammer, from the US, studying species survival of an arid Australian plant genus; * Trung Viet Nguyen, from Vietnam, studying DNA methylation in cancer development; * Sophie Monnier, from France, studying exploration geophysics focused on ocean bottom seismic data acquisition; and * UWA International student Grace Goh, from Singapore, studying circadian rhythms and temperature in metabolic function. In October 2013, the Forrests made what is believed to be the largest single philanthropic donation in Australian history – $65 million to attract the best minds to Western Australia. The donation included $50 million for the establishment of the Forrest Research Foundation to fund scholarships and postdoctoral fellowships across all five WA universities. A further $15 million will go towards the establishment of Forrest Hall – a new building to accommodate scholarship and fellowship recipients.
Views: 511 The University of Western Australia
Professor Brian Keating (https://briankeating.com/) is an astrophysicist with UC San Diego’s Department of Physics. He and his team develop instrumentation to study the early universe at radio, microwave and infrared wavelengths. He is the author of over 100 scientific publications and holds two U.S.Patents. He received an NSF CAREER award in 2006 and a 2007 Presidential Early Career Award for Scientists and Engineers at the White House from President Bush for a telescope he invented and deployed at the U.S. South Pole Research Station called “BICEP". Professor Keating became a Fellow of the American Physical Society in 2016. He co-leads the Simons Observatory (https://simonsobservatory.org/) Cosmic Microwave Background experiments in the Atacama Desert of Chile. His latest book, Losing the Nobel Prize: A Story of Cosmology, Ambition, and the Perils of Science's Highest Honor (link below), has been selected as one of Amazon.com’s Ten Best Nonfiction Books of the Month and one of Nature Magazine’s Six Best Books of the Season. Brian discusses the difficult problem of exploring the beginnings of the universe, moments after the Big Bang. His quest for the Nobel Prize in Physics was stymied when his experiment which was thought to have discovered definitive proof of the Big Bang ended up just being space dust. To add insult to injury, he was then asked to be part of the nominating committee for the following year’s Nobel Prize award. His journey of self-discovery and introspection opened his eyes to the ways in which the Nobel Prize process itself is broken, and has diverged from what was originally intended by its founder, Alfred Nobel. Get the book here: https://goo.gl/Y3wbbs
Views: 2371 Talks at Google
Universities are by no means universal: you can't expect them to create all kinds of opportunities for all kinds of people… they create some opportunities for some people, and what they can offer changes over time, in response to a variety of arbitrary and shifting factors (including the success, fundraising-ability and charisma of particular professors, as well as broader institutional considerations). This video does have a sequel ("Part 2 of 2") that you can get to from the end of the first video, or by following this link, here: https://youtu.be/KbaZvTPeHDI
Views: 2353 à-bas-le-ciel
The Genetic Basis of Kidney Cancer: Targeting the Metabolic Basis of Disease Air date: Wednesday, November 20, 2013, 3:00:00 PM Runtime: 01:05:55 Description: NIH Wednesday Afternoon Lecture Annual Astute Clinican Lecture Dr. Linehan has had a long-standing interest in identification of the genetic basis of cancer of the kidney. Kidney cancer is not a single disease. It is made up of a number of different types of cancer, each of which has a different histology, a different clinical course, which respond differently to therapy and are caused by different genes. Studies of the kidney cancer gene pathways have revealed that kidney cancer is fundamentally a metabolic disease. These findings have provided the foundation for the development of targeted therapeutic approaches for patients with advanced forms of this disease. The annual Astute Clinician lecture within the NIH Director's Wednesday Afternoon Lecture Series (WALS) highlights exciting clinical observations that have served as a focus for research. This series has been made possible through the generous gift of the late Dr. Robert W. Miller, Scientist Emeritus, National Cancer Institute and his wife, Haruko (Holly) Miller. For more information go to http://wals.od.nih.gov Author: Dr. Marston Linehan, Chief, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH Permanent link: http://videocast.nih.gov/launch.asp?18182
Views: 1344 nihvcast
Check out PhD student Roy Granit's latest Vlog in which he discusses his planned presentation for the prestigous 22nd Biennial European Association for Cancer Research (EACR) Congress. To learn more about IMRIC go to http://www.imric.org
Views: 127 IMRIC Medical Research
COMy - The 2nd World Congress on Controversies in Multiple Myeloma, April 28-30, 2016 Paris, France. A lecture on "Consolidation and Maintenance in Multiple Myeloma" by Paul G. Richardson, MD, RJ Corman Professor of Medicine, Harvard Medical School, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, UK. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, USA. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute before coming on staff at DFCI in 1994. Dr. Richardson currently holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He is the prior Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; The Tisch Outstanding Achievement Award for Clinical Research; and the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012, and received the Ernest Beutler Prize at ASH 2015. Dr. Richardson has published more than 280 original articles, and more than 180 reviews, chapters, and editorials in leading peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Clinical Cancer Research, and British Journal of Haematology. His primary research interest is in novel therapies, and he has been a leader in the clinical development of bortezomib, lenalidomide and pomalidomide. Currently, he is leading multiple efforts studying the use of combination therapies in relapsed and refractory myeloma, an area of primary interest to him, and he has pioneered the development of lenalidomide, bortezomib, and dexamethasone (so called RVD), which is now one of the most widely used combinations nationwide in the upfront treatment of myeloma. He is also serving as a principal investigator for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.
Views: 145 Tetsuzan Benny Ron
Speaker: Andrew Belmonte (Pennsylvania State University) Title: Games, Decisions, Evolution, and Chance Abstract: Humans play games. Sometimes we roll the dice, or buy lottery tickets - sometimes we play chess, or mind games of manipulation. History gives us two examples of the development of new mathematical ideas and directions from our playful habits: games of chance, which led to the formulation of Probability Theory, and games of strategy, which led to Game Theory. I will discuss how these two theories come together to provide a mathematical approach to conflict and other interactions for populations in biology, economics, and other situations where simple optimization does not explain what we see. Along the way, we will grapple with the challenges of cancer, and the dynamics of social media. Bio: Andrew Belmonte works at the intersection of mathematics and the sometimes surprising aspects of the world to which it can be applied - whether it be falling paper, breaking spaghetti, or strategic games. He received his PhD in Physics at Princeton University (1994), after which he did postdoctoral work at the Institut Non-Lineaire de Nice and the University of Pittsburgh. In 1998 he became a faculty member in mathematics at the Pennsylvania State University, and later the Department of Materials Science and Engineering (2010) and the Huck Institutes of the Life Sciences (2017). He was the recipient of an Alfred P. Sloan Fellowship (2000), an NSF CAREER Award (2001), and has held visiting positions at the ESPCI (France, 2004), Harvard University (SEAS, 2007), University of Maryland (IREAP, 2012), Universite Paris 7 (2013), and most recently at the National Cancer Institute, NIH, in Bethesda, MD (2016-17).
Views: 15 NCSU Mathematics
When Wendy Pogozelski began studying the primary literature in the field of nutrition, she was shocked to find enormous differences between the nutrition advice she’d found in the mainstream vs. the research and clinical results she was reading about. She connected with other researchers, doctors, biochemists and professors who had similar concerns and has become part of an international effort to help students, consumers and patients understand the science behind nutrition. Dr. Wendy Pogozelski received her B.S. in Chemistry from Chatham University and her PhD from The John Hopkins University. She was an Office of Naval Research post-doctoral fellow at the Naval Research Lab in Washington, D.C. In 1996, she came to Geneseo where she now holds the rank of Distinguished Teaching Professor and serves as Chair of the Chemistry Department. In her laboratory work, Dr. Pogozelski and her students investigate the effects of radiation on mitochondria. Since developing an interest in the biochemistry of nutrition, Dr. Pogozelski has been working with an international group of scientists and clinicians who are trying to bridge the gulf between scientific research and nutrition education. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Views: 151105 TEDx Talks
Dr. Sottery discusses Vitamin K-2 — a recently discovered nutrient that is critical to reducing Heart Disease and many forms of Cancer. Vitamin K-2 prevents arterial calcification by its action on MGP (Matrix GLA Protein).
Views: 3715 Dr. John Sottery
Title: Minimally competent Lewis acids for the synthesis of glycosides International Summit on Past and Present Research Systems of Green Chemistry August 25-27, 2014 Philadelphia, USA OMICS International: http://omicsonline.org Vaccine Conferences: http://conferenceseries.com/immunology-conferences.php Global Medical Conferences: http://conferenceseries.com Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com Global Cancer Conferences: http://cancersummit.org Global Diabetes Conferences: http://diabetesexpo.com Global Dental Conferences: http://dentalcongress.com Global Nursing Conferences: http://nursingconference.com Abstract: Classical glycosidation reactions have relied on the generation of very reactive glycosyl donors in conjunction with one or more equivalents of a promoter (Hg++, Ag+, etc). Newer methods have used trichloroacetimidates and strong Brønsted or Lewis acids, or thioglycosides in conjunction with oxidative or thiophilic activators. The use of more stable glycosyl peracetates in conjunction with stoichiometric amounts of strong Lewis acids (BF3•Et2O, FeBr3, etc) has been explored with limited success. The use of “minimally competent” Lewis acids has allowed us to perform glycosidation reactions with catalytic amounts of InBr3 or Bi(OTfl)3 well above room temperature and without significant decomposition of the glycoside products. The author will discuss the exploitation of these methods to produce glycolipid surfactants from renewable resources, as well as glycopeptide drugs that penetrate the blood-brain barrier (BBB). These drugs (“biousianglycopeptides”) are not subject to “Lipinski’s rules” that would otherwise eliminate them as CNS drug candidates. Glycosylated amphipathic helices or“address segments” have been used to target G-protein coupled receptors (GPCRs) in the brain after intravenous administration. The addition of glycoside moieties to endogenous peptide neurotransmitters and hormones imparts favorable pharmacokinetic and pharmacodynamics (PK/PD) properties to them, and permits BBB penetration. BBB penetration is not constrained by molecular weight considerations. Biography Robin Polt studied chemistry in the lab at IUPUI. After that he was trained in the art of Organic Synthesis in the laboratories of Professors Gilbert J. Stork at Columbia University and Dieter Seebach at the ETH in Zürich. He has continued to develop useful synthetic methods for amino acids, amino alcohols, glycosides and glycopeptides. He has mentored undergraduates, PhD students from the USA, Czech Republic, China, India, Iran, Ireland, Kenya, Korea, Mexico and Sri Lanka, as well as Post-doctoral students who have taken positions in academia, industry and government labs.
Views: 103 OMICS International
Shares of the global healthcare company, Novartis , are down after it saw its profits fall in the second quarter. The pharmaceuticals company saw earnings of $1.23 a share, which was four cents better than forecasts. The company is dealing with falling sales of its cancer drug, while its new heart drug has had a disappointing start in the U.S. Novartis also said its sales in 2016 will be "broadly in line" with last year's while core operating profit is expected to either be flat or decline. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Views: 89 TheStreet: Investing Strategies
Stem cell therapy: hype or hope? Lugano March 29, 2014 Some 200 people, largely university students, researchers and medical specialists, attended the Forum titled “Stem cell therapy: hype or hope?” held at the Auditorium of Università della Svizzera italiana in Lugano, Switzerland, on Saturday March 29, 2014. Organised by the Fondazione IBSA for Scientific Research, the forum provided a major opportunity for discussing where stem cell science stands today and its true potential going forward. Made possible thanks to the Foundation’s support, the meeting featured an intense scientific program with presentations made by high-calibre speakers who shared the key findings of their research. Speakers included Paolo Bianco (Director, Stem Cell Research, La Sapienza University, Rome, Italy), Pierre Gonczy (Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland), Shahragim Tajbakhsh (Director, Developmental & Stem Cell Biology Department, Pasteur Institute, Paris, France), Vania Broccoli (Head of the Stem Cells Research Unit, Neuroscience Division, San Raffaele Institute, Milan, Italy), Thomas Rando (Director, The Glenn Laboratories for the Biology of Aging, Stanford University School of Medicine, California, USA) and Austin Smith (Director, Wellcome Trust - Medical Research Council Stem Cell Institute, Cambridge University, UK). These world-class experts are driven by a common aspiration to be able to regenerate any damaged body parts and are fully aware that to develop and deliver effective therapies it is essential to get a full understanding of their benefits, limitations and risks.
Views: 149 IBSA Foundation for scientific research
Nobel Laureate Sir Paul Nurse, President of the Royal Society and Director of The Francis Crick Institute talks about his scientific career at The EMBO Meeting 2012 in Nice, France. Camera: Erik Malchow Sound: Julia Neig Director and Editor: Stefanie Trambow Producer: Katja Linssen Music: "Little Swing" by Roberto Daglio
Views: 1625 The EMBO Meeting
Carleton's Rowan Thomson has been awarded the 2011 Polanyi Prize for her valuable contribution to the field of physics. Thomson's research explores the development of computational techniques and approaches to the interactions of radiation with matter. Applications of her work are being used in diagnostic imaging, radiation protection, radiobiology and cancer treatment. Thomson has led the development of BrachyDose, a fast and accurate simulation for brachytherapy that can help the investigation of the physics of many brachytherapy treatments. "Winners of the Polanyi Prizes represent the best researchers our universities have to offer," said Ontario Minister of Training Glen Murray. "They are one of the reasons our post-secondary institutions are the sources of innovation that fuel our economy and help create tomorrow's jobs." Prior to joining the faculty of Carleton University in 2010, Thomson was a postdoctoral fellow and research associate in the Carleton Laboratory for Radiotherapy Physics. In addition to the Polanyi Prize, she has been awarded the L'Oreal Canada/UNESCO Women in Science Postdoctoral Research Excellence Fellowship and the Ministry of Research and Innovation of Ontario Postdoctoral Fellowship. "I was thrilled to find out that I won the award," said Thomson. "In research, you take leaps of faith and to win an award like this just reinforces the value of those leaps." About the Polanyi Prize: Ontario established the Polanyi Prizes in 1987 to honour the achievement of John Charles Polanyi, a 1986 Nobel Prize Laureate in chemistry. Every year, up to five prizes are given to researchers who are in the early stages of their careers and are pursuing postdoctoral research at an Ontario university.
Views: 1468 Carleton University
The European Commission presented today (30 November) its €80-billion research funding programme for the decade - Horizon 2020 - with the aim of boosting research, stimulating innovation and simplifying the way scientists and smaller businesses can get funding for EU-backed projects. The Horizon 2020 programme brings together all EU research and innovation funding under a single scheme running from 2014 to 2020. It replaces the Seventh Framework Programme for research (FP7), which expires in 2013. Defending Horizon 2020's launch in a time of austerity, EU Commissioner for Research, Innovation and Science Máire Geoghegan-Quinn said the programme would serve as a driver for European growth.
Views: 1081 EURACTIV
https://www.ibiology.org/genetics-and-gene-regulation/epigenetics/ In the first of his videos, Dr. Allis introduces the concept of epigenetics; a change in a cellular phenotype that is not due to DNA mutation but due to chemical modifications of proteins that result in changes in gene activation. In the nucleus, DNA is wrapped around proteins called histones to form chromatin. How tightly the chromatin is packaged determines whether genes are active or not. This switch between the “on and off” state of chromatin is regulated by chemical modification of histones. Allis describes work from his lab and others that identified the enzymes that add, remove and recognize the histone modifications. Changes in histone modification can cause a number of diseases including cancer. A key difference between genetic mutations and epigenetic modifications is that epigenetic changes are reversible making them an attractive drug target. Dr. Allis focuses on the role of epigenetics in development and disease in his second talk. Histones can be modified on a number of amino acids, particularly lysines, by the addition of acetyl or methyl groups. Combinatorial patterns of these modifications act to enhance or repress gene expression. Allis describes work from his lab and others, which demonstrates that mutations in histone (for instance a lysine to methionine mutation) may block these modifications and, thus, impact gene expression. Sadly, these “onco-histone” mutations have been identified as the cause of many diseases including pediatric brain tumors and pancreatic neuroendocrine tumors. Speaker Biography: C. David Allis is the Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University. Allis’ lab studies how modifications to histones, the proteins that package DNA, influence gene expression and the implications these changes have for human disease. Allis has been honored with many awards for his pioneering research including the 2015 Breakthrough Prize in Life Sciences, the 2014 Japan Prize, the 2007 Canada Gairdner International Award and many others. Allis is a member of the National Academy of Sciences USA, the American Academy of Arts and Sciences and the French Academy of Sciences. Allis received his BS in biology from the University of Cincinnati and his PhD in biology from Indiana University and he was a post-doctoral fellow at the University of Rochester.
Views: 16455 iBiology
Testimonial of Dr Youssef Idaghdour, winner of one of the Postdoctoral Scholarships for Excellence offered by the Sainte-Justine UHC Foundation and presented by the Sainte-Justine University Hospital Research Center. The scholarships are a veritable springboard for the careers of the world's future leaders in mother-child biomedical research. The three CAD$150,000 scholarships over three years, along with the CAD$15,000 seed funding will enable future postdoctoral students to carve out a niche for themselves in the 1st mother-child center in Canada and 4th in America. For more details about the competition, visit www.chu-sainte-justine.org/research/students/scholarships
Views: 502 Recherche SteJustine
SBBCollege's Lee Yarborough shares her experience as a career services coordinator, including how the College helps students become professionals in their chosen career field. SBBCollege Career Services offers job-placement assistance and job-obtaining skills, such as resume writing and interview techniques. Get a catalog, campus tour and more information at www.sbbcollege.edu
Views: 155 SBBCollege
This video demonstrates how the VCW is being used to support different PhDs across a wide range of topics. Over the years a wide range of doctoral programs have learned the VCW framework and doctoral and post-doctoral researchers have applied the VCW to support their work. The VCW has been used in several schools around the globe including Austria, Armenia, Belgium, China, Cyprus, Finland, France, Germany, Portugal, Slovenia, South Korea, Spain, UK, and USA. Schools of various disciplines (e.g., Business, Biotechnology, Chemistry, Entrepreneurship, Finance/Accounting, Law, Engineering, Medicine, Social Sciences, Sciences, Technology, and Tourism) have applied the VCW and its tools for research purposes and to solve real problems inside the classroom. VCW tools often appear in technical courses to solve specific challenges or courses of Value Creation, Tech-Transfer, Innovation Management, New Product Development, Marketing, Entrepreneurship, Strategy, International/Global Marketing, International Management, and International Business. Moreover, the VCW is providing Executives, MBAs, and Postgraduate students with a valuable opportunity to acquire rich and real experience in an effective way. The high percentage of Executives and MBAs that, after receiving the VCW training, have decided to implement the VCW in their own organizations demonstrates this fact. The VCW is also supporting a wide range of applied projects, Masters theses, as well as a Value Creation Field Lab. To learn more about the VCW and two decades of VCW cooperation with companies, executives, scientists, academics, and students across the world read: Lages, Luis Filipe (2016), "VCW—Value Creation Wheel: Innovation, technology, business, and society", Journal of Business Research.
Views: 124 Value Creation Wheel
Subscribe to Dr. Airan for daily Skin and Beauty Tips! Youtube - http://bit.ly/17hWgNc Twitter - http://www.twitter.com/DrLisaAiran Facebook - http://www.facebook.com/DrLisaAiran Pinterest - http://www.pinterest.com/DrLisaAiran A dermatologist whose Manhattan office specializes in aesthetic dermatology including BOTOX® Cosmetic and injectable fillers such as Restylane®, Radiesse® and JUVÉDERM®, Dr. Airan also performs laser hair removal in New York and uses lasers for scars, blood vessels, and reversal of sun damage. She performs Thermage® skin tightening, sclerotherapy, acne treatment, chemical peels, GentleWaves, general dermatology, and skin cancer surgery. Her high profile clients include a who's who list from the fashion industry, entertainment industry, A-list celebrities and modeling world. Best known for her 5 points to good living, Dr. Airan advocates balance through a healthy diet, regular exercise, spirituality, stress reduction, and cosmetic dermatology. Through this approach, Dr. Airan has emerged as an industry leader in her field. As a much profiled expert, she has appeared in countless fashion, beauty, and pop culture magazines as well as numerous newspaper and medical journal articles such as Vogue, Harper's Bazaar, W, Allure, Glamour, Teen Vogue, L'Officiel, L'Uomo Vogue, Vogue India, Lucky, In Style, Elle, British Elle, French Elle, Cosmopolitan, Jane, The New York Times, T, The New York Times Magazine, WWD, The Financial Times, US Weekly, Gotham, Hamptons, Aspen, and Shape. Dr. Airan is also a regular beauty expert for on camera commentary on today's most relevant beauty topics. She has appeared on Oprah, ABC Good Morning America, NBC's The Today Show, CNN, & MSNBC. More about Dr. Airan Dr. Airan received her medical degree at Northwestern University. She was awarded a Howard Hughes Medical Institute Research Scholarship at the National Institutes of Health which is one of a few prestigious fellowships awarded in the United States. After completing a one year Internship at the University of Chicago and a Dermatology residency at UCLA, Dr. Airan pursued her postdoctoral training with a fellowship in Mohs Micrographic Surgery at Washington University. Dr. Airan is certified by the American Board of Dermatology and the National Board of Medical Examiners. Dr. Airan's honors include the Albert M. Kligman Fellowship & the Richard B. Stoughton Memorial Fellowship. To meet with Dr. Airan, a dermatologist serving Manhattan and New York (NYC), request a consultation online or call (212) 400-0999 to schedule your appointment.
Views: 330 Lisa Airan, MD